These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 27546844)
1. Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. Martínez-Marín V; Maki RG Gastroenterol Clin North Am; 2016 Sep; 45(3):477-86. PubMed ID: 27546844 [TBL] [Abstract][Full Text] [Related]
2. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
3. Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS. Fredebohm J; Mehnert DH; Löber AK; Holtrup F; van Rahden V; Angenendt P; Diehl F Adv Exp Med Biol; 2016; 924():187-189. PubMed ID: 27753042 [TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Nishida T; Doi T; Naito Y Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162 [TBL] [Abstract][Full Text] [Related]
5. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
6. GEIS guidelines for gastrointestinal sarcomas (GIST). Poveda A; García Del Muro X; López-Guerrero JA; Cubedo R; Martínez V; Romero I; Serrano C; Valverde C; Martín-Broto J; Cancer Treat Rev; 2017 Apr; 55():107-119. PubMed ID: 28351781 [TBL] [Abstract][Full Text] [Related]
8. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192 [TBL] [Abstract][Full Text] [Related]
9. [Gastrointestinal stromal tumors (GIST)]. Jaros D; Bozic B; Sebesta C Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864 [TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors]. Xu J; Cao H Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353 [TBL] [Abstract][Full Text] [Related]
11. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568 [TBL] [Abstract][Full Text] [Related]
12. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series. Rutkowski P; Magnan H; Chou AJ; Benson C BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib]. Saito Y; Takahashi T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y Gan To Kagaku Ryoho; 2018 Jan; 45(1):121-123. PubMed ID: 29362328 [TBL] [Abstract][Full Text] [Related]
15. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib]. Hong JL; Li J; Li J; Shen L Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406 [TBL] [Abstract][Full Text] [Related]
16. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207 [TBL] [Abstract][Full Text] [Related]
17. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. Kim EJ; Zalupski MM J Surg Oncol; 2011 Dec; 104(8):901-6. PubMed ID: 22069175 [TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172 [TBL] [Abstract][Full Text] [Related]
19. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management]. Reichardt P; Reichardt A Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of regorafenib in colorectal cancer and GIST. Waddell T; Cunningham D Lancet; 2013 Jan; 381(9863):273-5. PubMed ID: 23177516 [No Abstract] [Full Text] [Related] [Next] [New Search]